2020, Number 1
<< Back Next >>
Invest Medicoquir 2020; 12 (1)
Trousseau syndrome as a manifestation of malignant neoplasms
Alfonso SA, Inguanzo VIB
Language: Spanish
References: 20
Page:
PDF size: 455.02 Kb.
ABSTRACT
A frequent diagnosis in cancer patients is venous thromboembolic disease. Trousseau syndrome was first described in 1865 and consists of the relationship between venous thromboembolic disease and cancer. This syndrome is characterized by a state of hypercoagulability in which multiple thromboembolic events occur, which may be the main symptomatology of the disease. It is common to observe these phenomena in cancer of pancreas, lung, breast, ovary, prostate, gastric, colo-rectal and gliomas. In addition, these events may be due to an adverse effect of the treatment, including some procedures, as well as the use of central venous pathways. A high percentage of these patients eventually die from thromboembolic manifestations. The diagnosis and treatment needs an interdisciplinary approach. Low molecular weight heparins have come to simplify patient treatments. Venous thromboembolic disease is a serious and frequent complication in cancer patients with high mortality, so efforts should be directed to make an early diagnosis and prevention will continue to be the most valuable and effective strategy.
Keywords: Trousseau syndrome, venous thromboembolic disease, cancer, fractionated heparins.
REFERENCES
Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic Review: The Trousseau Syndrome Revisited: Should We Screen Extensively for Cancer in Patients with Venous Thromboembolism?. Ann Intern Med 2008; 149: 323–33.
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 Feb 9;293(6):715-22.
Varki A. Ttrousseau´s Syndrome : multiple definitions and multiple mechanisms. Blood 2007 : 110 :1723-1729.
Stein P, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of Venous Thromboembolism in Patients Hospitalized with Cancer. The American Journal of Medicine. 2006; 19(1):60-68.
Noble S, Pasi J. Epidemiology and pathophysiologyof cancer associated to thrombosis. Br J Cancer 2010 ; 102: S2 – S9.
Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723–9.
Khorana AA. Venous Thromboembolism and Prognosis in Cancer. Thromb Res 2010; 125: 490–3.
Sorensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343:1846-1850
Becerra S. Cancer and venous thrombosis. Medwave 2007 Ene;7(1):e3385 doi: 10.5867/medwave.2007.01.3385
Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer. 2004 Oct;40(15):2253-9.
Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004 Aug 1;101(3):439-49.
Rus C, Bazzan M, Palumbo A, Bringhen S, Boccadoro M. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J ThrombHaemost. 2004 Nov;2(11):2063-5
Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188.
Rak J, Yu JL, Luyendyk J et al. Oncogenes, Trousseau Syndrome, and Cancer-Related Changes in the Coagulome of Mice and Humans. CancerResearch. 2006; 66(22): 10643-6.
Piccioli A, Lensing AW, Prins MH, etal.Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J ThrombHaemost. 2004 Jun;2(6):884-9.
Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):401S-428S
Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J ThrombHaemost. 2004 Oct;2(10):1760-5.
MerliGeno M.D. Old and new agents in the treatment of tromboembolicdisease.Hem/Onc Annals. 1993;1;2:113-122.
Preventing and Treating Blood Clots: Artículo citado en: http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/preventing-and-treating-blood-clots
Páramo JA, Panizo E, Lecumberri R. Profilaxis del tromboembolismo venoso en pacientes hospitalizados con cáncer. Rev Med Univ Navarra, 2008, 52(2): 9-13.